| Autor: |
Alberto Palazzuoli, Massimo Mancone, Gaetano M. De Ferrari, Giovanni Forleo, Gioel G. Secco, Gaetano M. Ruocco, Fabrizio D'Ascenzo, Silvia Monticone, Anita Paggi, Marco Vicenzi, Anna G. Palazzo, Maurizio Landolina, Erika Taravelli, Guido Tavazzi, Francesco Blasi, Fabio Infusino, Francesco Fedele, Francesco G. De Rosa, Michael Emmett, Jeffrey M. Schussler, Kristen M. Tecson, Peter A. McCullough |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 22 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2047-9980 |
| DOI: |
10.1161/JAHA.120.017364 |
| Popis: |
Background Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) utilizes the angiotensin‐converting enzyme‐2 (ACE‐2) receptor to enter human cells. Angiotensin‐converting enzyme inhibitors (ACEI) and angiotensin II receptor antagonists (ARB) are associated with ACE‐2 upregulation. We hypothesized that antecedent use of ACEI/ARB may be associated with mortality in coronavirus disease 2019 (COVID‐19). Methods and Results We used the Coracle registry, which contains data of patients hospitalized with COVID‐19 in 4 regions of Italy, and restricted analyses to those ≥50 years of age. The primary outcome was in‐hospital mortality. Among these 781 patients, 133 (17.0%) used an ARB and 171 (21.9%) used an ACEI. While neither sex nor smoking status differed by user groups, patients on ACEI/ARB were older and more likely to have hypertension, diabetes mellitus, and congestive heart failure. The overall mortality rate was 15.1% (118/781) and increased with age (PTrend |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text